Skip to main content
Premium Trial:

Request an Annual Quote

Myriad to Replace BRACAnalysis, Other Hereditary Cancer Tests with MyRisk Panel

NEW YORK (GenomeWeb News) – Myriad Genetics said during its analyst and investor day today that it will launch a new multi-hereditary cancer panel, called myRisk Hereditary Cancer, by the end of this year that will replace its existing BRACAnalysis and other hereditary cancer tests by the summer of 2015.

The new panel will initially focus on breast, colon, ovarian, endometrial, and pancreatic cancer, as well as melanoma, and will expand to lung, prostate, and other cancers in the future, Mark Capone, president of Myriad Genetics Laboratories, said.

It will initially contain 25 clinically actionable genes, several of which are protected by Myriad's intellectual property, that will be analyzed both for single-base changes and large rearrangements, primarily by next-generation sequencing.

The myRisk Hereditary Cancer panel will have a turnaround time of 14 days or less and a list price between $4,000 and $4,500, said Capone.

The panel currently includes eight genes proprietary to Myriad – BRCA1, BRCA2, BART, RAD51C, PALB2, PTEN, MYH, and P16. The company plans to add other such genes, including MITF and ELAC2, in the future.

By mid-2015, the new test will replace Myriad's BRACAnalysis, Colaris, Colaris AP, Melaris, and Panexia tests, which will be discontinued.

BRACAnalysis currently makes up the majority of Myriad's revenues. During the second quarter, the company recorded $115.4 million in revenues from this test and $16.9 million from the BRACAnalysis Large Rearrangement Test. Its total revenues for the quarter were $156.5 million, up 21 percent year over year.